Skip to content

Debiopharm Co-leads at 10M USD Collection A Spherical to Speed up the Growth of Genomic Medicines by way of Synthetic Intelligence

Debiopharm Innovation Fund strategically invests in Whitelab Genomics’ mission to make genomic medication growth sooner and leaner for extra environment friendly entry to most cancers sufferers sooner or later

LAUSANNE, Switzerland, Sept. 13, 2022 /CNW/ — Debiopharm Innovation Fund, the strategic funding arm of Swiss biopharmaceutical firm Debiopharm (, introduced at present their funding in Whitelab Genomics alongside French Enterprise Capital firm, Omnes Capital, in a $10 Million Collection A Spherical to advance their mission to speed up the event of genomics medicines by way of expertise powered by synthetic intelligence (AI). Whitelab Genomics’ computational platform reduces biotherapies’ growth time and price, enabling sooner entry to the market and cheaper therapeutic options out there for sufferers in want. Debiopharm’s funding in Whitelabs Genomics contributes to the expansion plan of the start-up’ R&D staff and US operations. Such an funding aligns with Debiopharm’s give attention to investing in digital well being options that enhance the most cancers affected person journey, rework pharmaceutical R&D, and shift healthcare in direction of a extra patient-centric strategy.

Based in 2019 by David Del BurgoMBA, and Julien CotineauPh.D., alongside a staff of world-class information scientists specialised in AI, computational biologists, molecular biologists, and genomic medication scientists, the start-up provides in-silico simulations custom-made for goal discovery, vector, and payload design, genotoxicity evaluation and identification of experimental protocols of in vitro and in vivo methods.

We’re transferring right into a time the place AI-based expertise will play a crucial function in drug growth. With higher methods to develop medication, de-risk property, de-risk any toxicity, and guarantee efficacy, we’re in a position to deliver extra customized medication to sufferers – that is exactly what Whitelab Genomics is confirmed to do,acknowledged Tanja DoweCEO of the Debiopharm Innovation Fund.

The worth of utilizing this AI-based platform is the potential acceleration of pre-clinical, translational stage, serving to drug analysis corporations rapidly design payloads and vectors and determine the very best experimental protocols for in vitro and in vivo assessments,stated Hamzeh Abdul HadiFunding Director of the Debiopharm Innovation Fund.

We’re very excited to shut this primary institutional funding spherical with such famend traders with deep data of the pharma surroundings. With this funding, we will proceed creating our proprietary information units and algorithms for each payload and vectors, and develop our collaborations with our clients.,” expressed David Del BurgoCEO and co-founder of Whitelab Genomics.

About Whitelab Genomics

WhiteLab Genomics, primarily based on Paris and cambridge (MA) was based in 2019 by David Del Burgo and Julien Cotineau, consultants in genomics drug growth and commercialization. WhiteLab Genomics goals to revolutionize genomic therapies growth utilizing private and non-private information and in-house AI algorithms. Whitelab Genomics helps its purchasers by way of the in-silico growth phases enabling them to rapidly develop goal vectors and payloads and save valuable time wanted to provide sufferers entry to new genomic therapies. In solely 2 years, Whitelab Genomics has satisfied main European and US Biotech and pharma to make use of its options for his or her new drug growth packages, together with RNA, DNA & Cell therapies. WhiteLab Genomics can be collaborating with world-renowned INSERM and Genethon laboratories and has been chosen by Y-Combinator in its Winter 2022 batch. The corporate has received a number of awards, together with the Galien Basis nominee for startups, the Alumni New Enterprise Fund from the Polsky Innovation Heart on the College of Chicagoand the Future 40 from Station F.

For extra data, please go to

About Debiopharm Innovation Fund

Debiopharm Innovation Fund, the strategic funding arm of Swiss biopharmaceutical firm Debiopharm, supplies strategic funding and steerage for corporations with an ambition to enhance the affected person journey, re-imagine how scientific trials are carried out, together with corporations providing digital platforms that help cutting-edge drug applied sciences. Since 2017 Debiopharm has invested in 14 digital well being corporations, sometimes main the funding rounds.

For extra data, please go to
We’re on Twitter. Comply with us @DebiopharmNews at

Debiopharm Contact

Daybreak Bonine
Head of Communications
[email protected]
Cellphone: +41 (0)21 321 01 11



View unique content material: through-artificial-intelligence-301623341.html

SOURCE Debiopharm Worldwide SA



View unique content material:

Leave a Reply

Your email address will not be published.